Abstract Form (The 56th Annual Meeting of the Japan Lung Cancer Society) First Author (Required) : Name Address E-mail Phone, Fax Authors & Institution (Required) : Please input the presenting author's and other authors' names and institutions. Maximum allowable number of authors:19 authors. Maximum allowable number of institutions:19 institutions. (ex.) Akihiko Gemma 1), Jitsuo Usuda 2)…/ 1) Dean of Medical School, Nippon Medical School, Department of pulmonary medicine and Oncology, Graduate School of Medicine, 2) Dean of Medical School, Nippon Medical School, Department of Respiratory Surgery Category (Required) : Category: Choose one category from the list below. 01. Epidemiology, Carcinogenesis, Risk-Factor 02. Mass Screening 03. Image Diagnosis 04. Nuclear Medicine 05. Biomarker 06. Prognostic Factor 07. Pathology 08. Oncogene 09. Molecular Biology 10. Cancer Immunology, Cytokine 11. Translational research 12. Airway Constriction/Stent 13. Bronchoscope (diagnosis and treatment) 14. Thoracoscope (diagnosis and treatment) 15. Metastasis (diagnosis and treatment) 16. Extended Surgery 17. Shrinking Surgery 18. Lymph Node Dissection 19. Cytodiagnosis, Thorax Lavage Cytodiagnosis 20. TNM classification, Stage classification 21. Adjuvant Therapy 22. Neoadjuvant Therapy 23. Radiotherapy 24. Chemoradiation 25. First-line Chemotherapy 26. Chemotherapy (Maintenance) 36. Thermotherapy/Radio Wave Treatment/PDT 37. Small Cell Lung Cancer Treatment 38. Relapsed Lung Cancer Treatment 39. Brain Metastasis Treatment 40. Multimodality 41. Palliative Care 42. Susceptibility and Resistance of Anti-Cancer Drug 43. Anti-Cancer Drug, PK 44. Side-effects Control 45. Lung Cancer Treatment and QOL 46. Lung Cancer and Infection 47. Carcinomatous Pleurisy, Carcinomatous Pericarditis 48. Juvenile Lung Cancer 49. Lung Cancer in the Elderly 50. Complication 51. Asbestos 52. Early Stage Small Lung Cancer 53. Multicentric Cancer, Multiple Primary Cancer 54. Neuroendocrine Tumor 55. Metastatic Tumor 56. Mediastinal Tumor 57. Pleural Mesothelioma 58. Multidisciplinary Care 59. Community Cooperation 60. Home Health Care 61. Chemotherapy for Outpatients Abstract Form (The 56th Annual Meeting of the Japan Lung Cancer Society) 27. Chemotherapy (Relapse Treatment) 28. Chemotherapy (Novel Drug) 29. Molecular Targeting Drug: EGFR-TKI 30. Molecular Targeting Drug: ALK Inhibitor 31. Molecular Targeting Drug: Angiogenesis Inhibitor 32. Molecular Targeting Drug: Novel Drug 33. Antibody, Vaccine Therapy 34. Genetic Treatment 35. Immunotherapy 62. Supporting Patients for Decision Making 63. Employment Support for Cancer Patients 64. Care for Patients Family 65. Patient Saloon 66. Survivorship 67. Cooperation of Hospital and Pharmacy 68. Grief Care 69. Case Report 70. Others Title of Abstract (Required) : The number of restriction characters becomes 100 characters. It cannot register, if this number of letters is exceeded. (ex.) Individualized afatinib dose adjustments facilitate continuous treatment Abstract Body (Required) : Enter the body of your abstract. Do not include the title, authors, or institutions. Place the first letter on the left end without a space. * within 1600 characters